A CD19-targeting allogenic CAR-T, using intracellular retention to prevent TCR expression, was tested in a Phase I study for non-Hodgkin’s lymphoma, showing no GvHD and a 75% ORR in the first eight patients (83). Here, CD19 is linked to non-Hodgkin lymphoma.